Brand Name
Ciplactin Tablet
๐น Composition
Each tablet contains:
-
Cyproheptadine Hydrochloride 4 mg
๐น Manufacturer
Cipla Ltd.
๐น Category
Antihistamine / Appetite stimulant
๐ Description
Ciplactin Tablet contains Cyproheptadine, an antihistamine with antiserotonergic and anticholinergic properties. It is commonly used for treating allergic conditions such as rhinitis, hay fever, and urticaria. Additionally, it is also prescribed as an appetite stimulant in patients with poor appetite and underweight conditions.
โ Indications / Uses
Ciplactin Tablet is indicated for:
-
Allergic disorders (hay fever, rhinitis, urticaria, conjunctivitis)
-
Skin allergies (itching, insect bites, dermatitis)
-
Appetite stimulant in patients with poor appetite, weight loss, or underweight
-
Migraine prophylaxis (in selected cases)
-
Other conditions as prescribed by a physician
๐ Dosage & Administration
-
Adults: Usually 1 tablet 2โ3 times daily (depending on condition).
-
Children (above 7 years): As prescribed by physician (usually lower dose).
-
To be taken with or without food.
-
Dosage must be individualized as per doctorโs advice.
โ ๏ธ Side Effects
Common:
-
Drowsiness, dizziness
-
Dry mouth, constipation
-
Increased appetite, weight gain
Serious (rare):
-
Confusion, blurred vision
-
Difficulty urinating
-
Severe allergic reactions (rash, swelling, breathing difficulty)
โ ๏ธ Precautions & Warnings
-
Contraindicated in patients allergic to cyproheptadine.
-
Avoid in newborns, lactating mothers, and elderly with glaucoma or urinary retention.
-
Use with caution in patients with liver disease, asthma, or cardiovascular conditions.
-
May cause drowsiness โ avoid driving or operating machinery.
-
Avoid alcohol during therapy.
๐ฆ Storage
-
Store below 30ยฐC, in a dry and cool place.
-
Protect from light and moisture.
-
Keep out of reach of children.
๐ท๏ธ Key Highlights
-
Antihistamine with appetite stimulant effect
-
Effective for allergies, skin reactions, and weight gain support
-
Convenient oral tablet form
Reviews
There are no reviews yet.